sb 203580 has been researched along with icaritin in 1 studies
Studies (sb 203580) | Trials (sb 203580) | Recent Studies (post-2010) (sb 203580) | Studies (icaritin) | Trials (icaritin) | Recent Studies (post-2010) (icaritin) |
---|---|---|---|---|---|
3,489 | 4 | 1,137 | 202 | 1 | 178 |
Protein | Taxonomy | sb 203580 (IC50) | icaritin (IC50) |
---|---|---|---|
cGMP-specific 3',5'-cyclic phosphodiesterase | Homo sapiens (human) | 2.2 |
Timeframe | Studies, this research(%) | All Research% |
---|---|---|
pre-1990 | 0 (0.00) | 18.7374 |
1990's | 0 (0.00) | 18.2507 |
2000's | 0 (0.00) | 29.6817 |
2010's | 1 (100.00) | 24.3611 |
2020's | 0 (0.00) | 2.80 |
Authors | Studies |
---|---|
Liu, H; Ou, L; Sun, K; Wang, C; Wang, P; Wu, Z; Xiong, Y; Yang, L; Zhang, R; Zhu, X | 1 |
1 other study(ies) available for sb 203580 and icaritin
Article | Year |
---|---|
Icaritin induces MC3T3-E1 subclone14 cell differentiation through estrogen receptor-mediated ERK1/2 and p38 signaling activation.
Topics: Animals; Cell Differentiation; Cell Line; Cell Survival; Clone Cells; Enzyme Activation; Extracellular Signal-Regulated MAP Kinases; Flavonoids; Imidazoles; MAP Kinase Signaling System; Mice; p38 Mitogen-Activated Protein Kinases; Pyridines; Receptors, Estrogen | 2017 |